

09/936499
5060

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/06910 A3

(51) International Patent Classification⁷: C12Q 1/68,
C07H 21/04

(21) International Application Number: PCT/US00/06502

(22) International Filing Date: 10 March 2000 (10.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/124,060 12 March 1999 (12.03.1999) US

(71) Applicant (for all designated States except US): UNI-
VERSITY OF CINCINNATI [US/US]; Box 670829,
3223 Eden Avenue, Wherry Hall G7, Cincinnati, OH
45267-0829 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): LIGGETT, Stephen,
B. [US/US]; 8020 Elbrecht Drive, Cincinnati, OH 45242
(US).

(74) Agent: HENDERSON, Melodie, W.; Genaissance Phar-
maceuticals, INC., Five Science Park, New Haven, CT
06511 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
27 September 2001

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: VARIATION IN DRUG RESPONSE RELATED TO POLYMORPHISMS IN β_2 -ADRENERGIC RECEPTOR

(57) Abstract: A method for predicting an individual's response to the β -agonists salmeterol, albuterol, metaproterenol, terbutaline and formoterol is disclosed. Individuals expressing the Ile164 β_2 AR variant are likely to exhibit a reduced response as compared to individuals expressing the Thr164 β_2 AR variant. The method is useful for making treatment decisions for patients suffering from asthma and chronic obstructive pulmonary diseases.

WO 01/06910 A3